{'fraction_non_alphanumeric': 0.030303030303030304, 'fraction_numerical': 0.010101010101010102, 'mean_word_length': 5.4471544715447155, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations

The main aim of this study was to test the effect of the triazolo‐benzodiazepine, estazolam, on auditory hallucinations. Fifty‐eight patients (28 male, 30 female) with auditory hallucinosis that had responded poorly to neuroleptics alone, were included; most patients were chronic schizophrenics, and most patients were maintained on previous neuroleptic treatment during the trial. Each patient was treated for three consecutive 3‐week periods, and randomly allocated to receive estazolam (1 + 1 + 4 mg) either in the first and third, or in the second period. Similar‐looking placebo tablets were given in the control periods. There were seven dropouts, three of them due to somnolence on estazolam.